On March 18, 2025, Robert Mauch, President & CEO of a branch of Cencora Inc (COR, Financial), sold 4,970 shares of the company. Following this transaction, the insider now owns 49,326 shares of Cencora Inc. The details of this transaction can be found in the SEC Filing.
Cencora Inc is a company that operates in the healthcare sector, providing pharmaceutical distribution and related services. The company plays a crucial role in the supply chain, ensuring that medications and healthcare products are delivered efficiently to healthcare providers and patients.
Over the past year, Robert Mauch has sold a total of 67,504 shares and has not made any purchases. The insider transaction history for Cencora Inc indicates that there has been 1 insider buy and 23 insider sells over the same period.
On the day of the recent sale, shares of Cencora Inc were trading at $260.93, giving the stock a market cap of $52.157 billion. The company's price-earnings ratio stands at 38.30, which is higher than the industry median of 18.915 and also higher than the company’s historical median price-earnings ratio.
With a trading price of $260.93 and a GF Value of $239.63, Cencora Inc has a price-to-GF-Value ratio of 1.09, indicating that the stock is modestly overvalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples, a GuruFocus adjustment factor, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
